Efficacy of Rezūm water vapor therapy for the treatment of catheter-dependent urinary retention

A single-center, Canadian experience

Authors

  • Ryan Ramjiawan Section of Urology, Department of Surgery, University of Manitoba
  • David Chung Section of Urology, Department of Surgery, University of Manitoba
  • Maximilian G. Fidel Max Rady College of Medicine, University of Manitoba
  • Harliv Dhillon Men’s Health Clinic, Winnipeg, MB
  • Dhiraj S. Bal Max Rady College of Medicine, University of Manitoba
  • Alagarsamy Pandian Department of Anesthesia, University of Manitoba
  • Robert Bard Men’s Health Clinic, Winnipeg, MB
  • Jasmir G. Nayak Section of Urology, University of Manitoba; Men's Health Clinic, Winnipeg, MB
  • Premal Patel Section of Urology, University of Manitoba; Men's Health Clinic, Winnipeg, MB

DOI:

https://doi.org/10.5489/cuaj.8808

Keywords:

urinary retention, urinary catheterization, benign prostatic hyperplasia, minimally invasive surgical procedures

Abstract

INTRODUCTION: Urinary retention secondary to benign prostatic hyperplasia (BPH) requiring catheterization is a prevalent and morbid condition. The objective of this study was to evaluate the real-world efficacy and safety of Rezūm as the primary treatment of catheter-dependent urinary retention.

METHODS: A single-center, retrospective study analyzed patients with catheter-dependent urinary retention secondary to BPH who were treated with Rezūm between April 2022 and April 2024. Standardized postoperative followup was required for inclusion. Patient demographics, medication use, volume drained at time of urinary retention, catheter-free status, complications, and postoperative International Prostate Symptom Score (IPSS) was collected.

RESULTS: A total of 53 patients were included. Mean age was 73.4 years (standard deviation 9.4), and the mean Charlson comorbidity index score was 3.7. The baseline mean prostate volume was 81.7 (range 33–179) mL. Patients were catheter-dependent for an average of 225 (range 30–1821) days prior to surgical intervention. Average followup time was 10.2 months. Of the 53 patients treated, 42 (79%) patients were able to become catheter-free after treatment. Twenty-six (49%) patients failed their initial trial of void at 14 days postoperatively; 11% (n=6) of patients experienced hematuria with one admitted to hospital due to hematuria/clot retention. There were no Clavien-Dindo >3 complications. Only retention volume ≥1 L was a significant independent predictor of treatment failure on univariate and multivariate logistic regression analysis.

CONCLUSIONS: Rezūm effectively treated catheter-dependent urinary retention. Given the simplicity of treatment, accessibility, and minimal anesthetic requirements, providers should consider Rezūm to minimize indwelling catheter-related morbidity for catheter-dependant patients.

Downloads

Download data is not yet available.

Downloads

Published

2024-08-30

How to Cite

Ramjiawan, R., Chung, D., Fidel, M. . G., Dhillon, H., Bal, D. S., Pandian, A., … Patel, P. (2024). Efficacy of Rezūm water vapor therapy for the treatment of catheter-dependent urinary retention: A single-center, Canadian experience. Canadian Urological Association Journal, 19(1), E18–24. https://doi.org/10.5489/cuaj.8808

Issue

Vol. 19 No. 1 (2025): CUAJ January

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.